Study of the clinical utility and safety in combination use of the GLI-1 analogue and Insulin degludec in type 2 diabetic patients.

Study of the clinical utility and safety in combination use of the GLI-1 analogue and Insulin degludec in type 2 diabetic patients. - Study of the clinical utility and safety in combination use of the GLI-1 analogue and Insulin degludec in type 2 diabetic patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016966

Enrollment

Registered

2015-03-30

Start date

2013-06-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Despite while using liraglutide , deterioration in glycemic control , or administered to a patient in weight gain.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with written IC. 2)Patients who use Liraglutide of Deterioration. 3)HbA1c (NGSP):more than 6.2%.

Exclusion criteria

Exclusion criteria: 1)Patients with advanced diabetic complications. 2)Patients with to the contraindication of GLP-1 receptor agonist (Victoza subcutaneous injection18mg) (Liraglutide) 3)Patients with to the contraindication of the long acting insulin analog formulation (Tresiba Injection) (Degludec) 4)Patients judged by the investigator to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
change of HbA1c	—

Countries

Japan

Contacts

Public ContactWakana Miura

Department of Internal Medicine, Tokai University School of Medicine Division of Nephrology, Endocrinology and Metabolism

happy0897@gmail.com0563-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026